Mitochondrial activity and oxidative stress markers in peripheral blood mononuclear cells of patients with bipolar disorder, schizophrenia, and healthy subjects

Journal of Psychiatric Research

Volumn 47, Issue 10, 2013, Pages 1396-1402

  Gubert, Carolina ^a,b,c   Stertz, Laura ^a,b,c   Pfaffenseller, Bianca ^a,b,c   Panizzutti, Bruna Schilling ^a,b   Rezin, Gislaine Tezza ^b,d   Massuda, Raffael ^a,b   Streck, Emilio Luiz ^b,d   Gama, Clarissa Severino ^a,b   Kapczinski, Flávio ^a,b   Kunz, Maurício ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b Instituto Nacional de Ciencia e Tecnologia Translacional em Medicina INCT TM   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Bipolar disorder; Electron transport chain; Mitochondria; Oxidative stress; Schizophrenia

Indexed keywords

THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME KINETICS; FEMALE; HUMAN; LIPID OXIDATION; LIPID PEROXIDATION; MALE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RESPIRATORY CHAIN; SCHIZOPHRENIA;

BIPOLAR DISORDER; ELECTRON TRANSPORT CHAIN; MITOCHONDRIA; OXIDATIVE STRESS; SCHIZOPHRENIA;

ADULT; BIPOLAR DISORDER; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPID PEROXIDATION; MALE; MIDDLE AGED; MITOCHONDRIA; OXIDATIVE STRESS; PROTEIN CARBONYLATION; SCHIZOPHRENIA; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84881557425     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.06.018     Document Type: Article

References (39)

1. Andreazza A.C., Shao L., Wang J.F., Young L.T. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Archives of General Psychiatry 2010, 67:360-368.
2. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., et al. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biological Psychiatry 2003, 53:56-64.
3. Ben-Shachar D. The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia. Journal of Neural Transmission 2009, 116:1383-1396.
4. Ben-Shachar D., Zuk R., Gazawi H., Reshef A., Sheinkman A., Klein E. Increased mitochondrial complex I activity in platelets of schizophrenic patients. The International Journal of Neuropsychopharmacology 1999, 2:245-253.
5. Berk M., Ng F., Dean O., Dodd S., Bush A.I. Glutathione: a novel treatment target in psychiatry. Trends in Pharmacological Sciences 2008, 29:346-351.
6. Blanchet L., Buydens M.C., Smeitink J.A., Willems P.H., Koopman W.J. Isolated mitochondrial complex I deficiency: explorative data analysis of patient cell parameters. Current Pharmaceutical Design 2011, 17:4023-4033.
7. Bradford M.M. Arapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 1976, 72:248-254.
8. Brenner-Lavie H., Klein E., Zuk R., Gazawi H., Ljubuncic P., Ben-Shachar D. Dopamine modulates mitochondrial function in viable SH-SY5Y cells possibly via its interaction with complex I: relevance to dopamine pathology in schizophrenia. Biochimica et Biophysica Acta 2008, 1777:173-185.
9. Burkhardt C., Kelly J.P., Lim Y.H., Filley C.M., Parker W.D. Neuroleptic medications inhibit complex I of the electron transport chain. Annals of Neurology 1993, 33:512-517.
10. Casademont J., Garrabou G., Miró O., López S., Pons A., Bernardo M., et al. Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. Journal of Clinical Psychopharmacology 2007, 27:284-288.
11. Cassina A., Radi R. Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport. Archives of Biochemistry and Biophysics 1996, 328:309-316.
12. Chua B.T., Volbracht C., Tan K.O., Li R., Yu V.C., Li P. Mitochondrial translocation of cofilin is an early step in apoptosis induction. Nature Cell Biology 2003, 5:1083-1089.
13. Dietrich-Muszalska A., Kontek B. Lipid peroxidation in patients with schizophrenia. Psychiatry and Clinical Neurosciences 2010, 64:469-475.
14. Dietrich-Muszalska A., Olas B., Rabe-Jablonska J. Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005, 16:386-391.
15. Fischer J.C., Ruitenbeek W., Berden J.A., Trijbels J.M., Veerkamp J.H., Stadhouders A.M., et al. Differential investigation of the capacity of succinate oxidation in human skeletal muscle. Clinica Chimica Acta 1985, 153:23-36.
16. Green D.R., Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004, 305:626-629.
17. Hamilton M. Arating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 1960, 23:56-62.
18. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophrenia Bulletin 2009, 35:549-562.
19. Kapczinski F., Dal-Pizzol F., Teixeira A.L., Magalhaes P.V., Kauer-Sant'Anna M., Klamt F., et al. Peripheral biomarkers and illness activity in bipolar disorder. Journal of Psychiatric Research 2011, 45:156-161.
20. Karry R., Klein E., Ben Shachar D. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biological Psychiatry 2004, 55:676-684.
21. Kegeles L.S., Humaran T.J., Mann J.J. Invivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biological Psychiatry 1998, 44:382-398.
22. Kunz M., Ceresér K.M., Goi P.D., Fries G.R., Teixeira A.L., Fernandes B.S., et al. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Revista Brasileira de Psiquiatria 2011, 33:268-274.
23. Leuner K., Schulz K., Schütt T., Pantel J., Prvulovic D., Rhein V., et al. Peripheral mitochondrial dysfunction in Alzheimer's disease: focus on lymphocytes. Molecular Neurobiology 2012, 46:194-204.
24. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G., et al. Determination of carbonyl content in oxidatively modified proteins. Methods in Enzymology 1990, 186:464-478.
25. Magalhães P.V., Jansen K., Pinheiro R.T., Colpo G.D., da Motta L.L., Klamt F., et al. Peripheral oxidative damage in early-stage mood disorders: a nested population-based case-control study. The International Journal of Neuropsychopharmacology 2011, 1-8.
26. Manji H., Kato T., Di Prospero N.A., Ness S., Beal M.F., Krams M., et al. Impaired mitochondrial function in psychiatric disorders. Nature Reviews Neuroscience 2012, 13:293-307.
27. Mattson M.P. Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxidants & Redox Signalling 2006, 8:1997-2006.
28. Maurer I., Möller H.J. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Molecular and Cellular Biochemistry 1997, 174:255-259.
29. Mutisya E.M., Bowling A.C., Beal M.F. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. Journal of Neurochemistry 1994, 63:2179-2184.
30. Park C., Park S.K. Molecular links between mitochondrial dysfunctions and schizophrenia. Molecules and Cells 2012, 33:105-110.
31. Parker W.D., Filley C.M., Parks J.K. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 1990, 40:1302-1303.
32. Pedrini M., Massuda R., Fries G.R., de Bittencourt Pasquali M.A., Schnorr C.E., Moreira J.C., et al. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. Journal of Psychiatric Research 2012, 46:819-824.
33. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Research 2003, 121:109-122.
34. Uranova N., Orlovskaya D., Vikhreva O., Zimina I., Kolomeets N., Vostrikov V., et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Research Bulletin 2001, 55:597-610.
35. Valvassori S.S., Rezin G.T., Ferreira C.L., Moretti M., Gonçalves C.L., Cardoso M.R., et al. Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. Journal of Psychiatric Research 2010, 44:903-909.
36. Volz H.R., Riehemann S., Maurer I., Smesny S., Sommer M., Rzanny R., et al. Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: a (31)P chemical shift spectroscopic-imaging study. Biological Psychiatry 2000, 47:954-961.
37. Whatley S.A., Curti D., Das Gupta F., Ferrier I.N., Jones S., Taylor C., et al. Superoxide, neuroleptics and the ubiquinone and cytochrome b5 reductases in brain and lymphocytes from normals and schizophrenic patients. Molecular Psychiatry 1998, 3:227-237.
38. Whatley S.A., Curti D., Marchbanks R.M. Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochemical Research 1996, 21:995-1004.
39. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. Arating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 1978, 133:429-435.